# Hand-Held Colposcopes Market

> Hand-held colposcopes: USD 75.4 million in 2025, USD 149.1 million by 2035, as WHO screen-and-treat targets push portable colposcopy into outreach.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10570  
Published: 2026-10-07  
Last updated: 2026-10-07  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/hand-held-colposcopes-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $75.4 Mn | 25,870 hand-held colposcopes times USD 2,915 average price equals USD 75.4 million. |
| Forecast · 2035 | $149.1 Mn | 6.1% unit growth and 0.9% price growth compounded for ten years. |
| Revenue CAGR · 2026-2035 | 7.06% | Multiplicative volume and price legs. |
| Volume · 2035 | 46,768 units | 25,870 units in 2025 grown at 6.1% a year. |
| Leading segment | Digital video, 46.1% | USD 34.8 million on about 7,820 units at USD 4,450. |
| Fastest segment | Smartphone-based, 10.1% | Telecolposcopy and nurse-led screen-and-treat favour phone-coupled capture. |
| Fastest region | Middle East and Africa, 10.43% | Africa carries 20.6% of new cervical cancer cases but 7.4% of device revenue. |
| Market leader | MobileODT, est. 17.2% | Douglas Insights estimate from unit and price model; no segment revenue disclosed. |
| Event | FDA 510(k) K233043, 14 Jun 2024 | Periwinkle Technologies Smart Scope CX found substantially equivalent. |

## Key takeaways

- Hand-held colposcopes generate USD 75.4 million in 2025 and USD 149.1 million in 2035, a 7.06% revenue CAGR.
- Digital video units lead with 46.1% of value, while smartphone-based colposcopes grow fastest at 10.1% a year.
- The Middle East and Africa grow 10.43% a year, yet spend only about USD 45 per new cervical cancer case against USD 1,550 in North America.
- MobileODT leads with an estimated 17.2% share, and the top three hand-held specialists hold about 35.5%.
- Each extra point of unit growth adds USD 14.6 million to the 2035 value, taking it to USD 163.7 million.

A health ministry that orders through UNICEF Supply Division pays [USD 2,050 for a portable colposcope kit](https://supply.unicef.org/s0004076.html) with a monopod stand, phone holder, lithium-ion battery and green filters, and that line item frames every hand-held colposcope budget we model. Hand-held colposcopes are battery or mains powered magnifiers of 5x to 15x that a clinician holds or mounts on a light monopod to inspect the cervix, vagina and vulva after acetic acid; the Hand-Held Colposcopes market covers optical, digital video and smartphone-based units sold to hospitals, clinics and screening programmes. Douglas Insights puts 2025 revenue at USD 75.4 million, built as 25,870 units shipped times a USD 2,915 average realised price, and projects USD 149.1 million in 2035, a 7.06% revenue CAGR. The US Food and Drug Administration cleared the Smart Scope CX from Periwinkle Technologies of Pune on [14 June 2024](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233043), a smartphone-era device now competing with stand-mounted optics. The study belongs to our [diagnostic devices](https://www.douglasinsights.com/industry/healthcare/medical-devices/diagnostic-devices/) coverage, and every figure follows the [Douglas Insights research methodology](https://www.douglasinsights.com/research-methodology/).

## Why are screen-and-treat programmes buying hand-held colposcopes faster than clinics retire stand-mounted scopes?

Unit shipments of hand-held colposcopes rise 6.1% a year to 2035. The WHO 90-70-90 elimination targets push screen-and-treat programmes, office gynecology swaps floor stands for portable digital units, and nurse-led telecolposcopy needs a device per outreach team rather than per hospital.

Programme scale-up is the largest pull at 2.6 points of the 6.1-point volume leg. The [WHO cervical cancer fact sheet](https://www.who.int/news-room/fact-sheets/detail/cervical-cancer) counts around 604,000 new cases and around 280,000 deaths, with the highest incidence and mortality in low- and middle-income countries. Its targets ask for 90% of girls vaccinated by 15, 70% of women screened with a high-performance test by 35 and again by 45, and 90% of women with precancer or cancer treated. Every HPV-positive woman who needs a look at the transformation zone before ablation adds colposcopy demand, and a hand-held colposcope at roughly USD 2,000 fits a district budget where a stand-mounted video system, which Douglas Insights prices near USD 9,000, does not.

Replacement of stand-mounted optics in private gynecology adds 1.9 points. A floor-stand binocular colposcope needs a dedicated room, while a hand-held colposcope with an HD sensor stores images straight into the patient record. Douglas Insights estimates that 34.8 million US dollars, or 46.1% of 2025 hand-held colposcope revenue, already comes from digital video units, the format that clinics pick when they retire analog scopes. Clinics that buy a hand-held unit also cut the time a second clinician spends reviewing images, because a stored still or clip travels by message instead of by appointment.

Task shifting and telecolposcopy add the final 1.6 points. Smartphone-based colposcopes let a nurse capture the cervix, apply the green filter and send the image to a remote colposcopist, which turns one specialist into a hub for several screening sites. Periwinkle Technologies took its Smart Scope CX through a US 510(k) on [14 June 2024](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233043), a sign that phone-coupled colposcopes are moving from donor pilots into regulated commercial channels. Douglas Insights tallies 10,046 smartphone-based colposcopes shipped in 2025, about 38.8% of all hand-held units, and that format grows at 10.1% a year by value.

Added together, the three hand-held colposcope drivers give 2.6 plus 1.9 plus 1.6, or 6.1 points of annual unit growth. The price leg of 0.9% a year is separate and comes from the mix shift toward video units with image analysis software.

## What slows hand-held colposcope volumes when HPV-negative women wait five years between tests?

Three restraints would take about 1.9 points off hand-held colposcope unit growth in the slower case. They are longer screening intervals in rich systems, supplier exits that strand installed bases, and donor-funded procurement that buys in lumps rather than steadily.

Longer intervals remove up to 0.8 points. On [1 July 2025](https://www.gov.uk/government/publications/extended-screening-interval-clinical-pathway-protocol/extended-screening-interval-clinical-pathway-protocol) GOV.UK published the extended screening interval clinical pathway protocol, under which participants aged 24.5 to 49 who test negative on a routine primary high-risk human papillomavirus (hrHPV) test move from a 3-year to a 5-year interval. Fewer routine screens mean fewer borderline referrals, so the replacement cycle for colposcopes in England and in systems that copy it stretches out.

Supplier exits remove 0.6 points in the slower case. DYSIS Medical, maker of the DYSIS View and DYSIS Ultra digital colposcopes with computer-aided cervical mapping, states on [its own site](https://www.dysismedical.com/) that it was acquired by Apgar Danmark A/S effective 4 February 2025 and ceased operations on 24 April 2025. Buyers who watched an installed base lose its service partner now ask hand-held colposcope vendors for longer warranties, such as the three-year cover in the UNICEF specification, and that slows tender closes.

Lumpy donor funding removes 0.5 points. Douglas Insights expects about 26.0% of hand-held colposcope value, USD 19.6 million in 2025, to flow through community screening programmes, and those orders arrive in grant cycles of one to three years rather than as steady replacement.

## Which product type leads hand-held colposcope revenue: digital video, smartphone or optical?

Digital video hand-held colposcopes lead with 46.1% of 2025 revenue, USD 34.8 million. Hospitals and private clinics want stored HD images, while smartphone-based units grow fastest at 10.1% a year, and optical units trail at 3.1% as buyers move from eyepieces to screens.

| Product type | Share of 2025 revenue | Value 2025 | Value CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Digital video hand-held colposcopes | 46.1% | USD 34.8 million | 6.6% | USD 65.9 million |
| Smartphone-based colposcopes | 29.1% | USD 21.9 million | 10.1% | USD 57.3 million |
| Optical hand-held colposcopes | 24.8% | USD 18.7 million | 3.1% | USD 25.4 million |

Digital video hand-held colposcopes earn USD 34.8 million on about 7,820 units at an average of USD 4,450, because an integrated sensor, LED head and documentation software justify a premium in insured markets. Smartphone-based colposcopes earn USD 21.9 million on 10,046 units at about USD 2,180, the format that ministries and NGOs buy for outreach because the phone carries the screen, storage and upload. Optical hand-held colposcopes earn USD 18.7 million on 8,004 units near USD 2,336, held up by buyers who want binocular depth without software or batteries.

Smartphone-based colposcopes are the fastest segment at 10.1% a year, reaching USD 57.3 million in 2035, because telecolposcopy and nurse-led screening reward a low-cost capture device over magnification range. Optical hand-held colposcopes grow 3.1% and fall to about 17% of value by 2035.

The channel split follows the buyer: Direct sales serve teaching hospitals and large gynecology groups, Distributors carry most private clinic orders in Asia and Latin America, and Public tenders and procurement agencies such as UNICEF set the reference price for programme buyers.

## Which buyers, from hospitals to community screening programmes, hold the colposcope budget?

Hospitals spend USD 29.0 million on hand-held colposcopes in 2025, 38.4% of value. Gynecology clinics follow at USD 26.8 million and Community screening programmes at USD 19.6 million, because hospitals still run most referral colposcopy and biopsy lists and buy the dearest video units.

Hospitals buy the dearest digital video hand-held colposcopes, often as a second unit beside a stand-mounted scope for wards, satellite clinics and emergency gynecology. Douglas Insights reckons the hospital share slips by about 2.5 points by 2035 as programme buying grows faster. Gynecology clinics, holding 35.6% of value, replace on a seven- to nine-year cycle and favour colposcopes that file images into practice software. Community screening programmes, with 26.0% of value, buy smartphone-based and battery optical units in batches of 50 to 500 for mobile teams.

Readers tracking the downstream procedure should pair this view with our [Biopsy Devices Market](https://www.douglasinsights.com/biopsy-devices-market/) study, because each directed cervical biopsy starts with a colposcope image.

## Where do hand-held colposcopes sell, and how far does the Africa case burden outpace device revenue?

North America leads with USD 23.9 million of 2025 hand-held colposcope revenue, 31.7% of the world total. The Middle East and Africa grow fastest at 10.43% a year, as screen-and-treat programmes add outreach teams and buy battery-powered units for district clinics.

North America reaches USD 39.7 million in 2035 at 5.2% a year, supported by digital video replacement and 510(k)-cleared image capture. Europe records USD 20.7 million in 2025 and USD 33.7 million in 2035 at 5.0%, the slowest rate because primary HPV testing and longer intervals trim referral growth. Asia Pacific starts at USD 18.5 million and climbs to USD 46.3 million at 9.6% a year, carried by large national programmes and local makers such as Periwinkle in India.

Latin America moves from USD 6.7 million to USD 14.3 million at 7.9%, with public tenders dominating. The Middle East and Africa start smallest at USD 5.6 million but reach USD 15.1 million in 2035 at 10.43%, the fastest regional rate, because donor-funded procurement buys hand-held colposcopes rather than fixed equipment for district hospitals. The wildcard is Asia Pacific: one national tender for smartphone-based colposcopes in a populous country could add more units in a year than Europe buys in three.

## Which companies win hand-held colposcope tenders, from MobileODT to Periwinkle Technologies?

Douglas Insights estimates the top three hand-held colposcope specialists hold about 35.5% of 2025 revenue. MobileODT, Periwinkle Technologies and Gynius form that group, with MobileODT the leader at an estimated 17.2% share; the basis is our unit and price model, since none of them reports segment revenue.

MobileODT of Tel Aviv built its position on the EVA and EVAPro digital colposcopes, which pair a light handheld body with Wi-Fi image sharing and the VisualCheck scoring software; the company has described training that software on exams from 17 countries. Periwinkle Technologies of Pune holds an estimated 11.9% share on the Smart Scope CX, cleared by the FDA on [14 June 2024](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233043) under 510(k) K233043. Gynius AB of Stockholm, holding an estimated 6.4%, built its name on the Gynocular, a battery binocular colposcope that received FDA clearance K132423 on 8 April 2014.

Three stand-mounted makers compete for the same budget line. CooperSurgical sells the Leisegang OptiK Model 1 with 3-step magnification and 24,000 lux LED light at a 300 mm working distance. ATMOS MedizinTechnik of Lenzkirch sells the ATMOS i View 21 and 31 COLPO with five magnification steps from 4.3x to 17x and HD cameras. Karl Kaps of Asslar, producing optics in Germany since 1946, supplies colposcopes with multiple magnification levels and LED lighting.

The seventh name is a warning. DYSIS Medical, whose DYSISmap quantified acetowhitening, was acquired by Apgar Danmark A/S effective 4 February 2025 and wound down from 24 April 2025, according to [the DYSIS Medical site](https://www.dysismedical.com/). That exit leaves a gap in computer-aided mapping that hand-held colposcope makers with AI scoring now target.

| Company | Base | Hand-held colposcope position | Estimated 2025 share |
| --- | --- | --- | --- |
| MobileODT | Tel Aviv, Israel | EVA and EVAPro digital units with VisualCheck AI | 17.2% |
| Periwinkle Technologies | Pune, India | Smart Scope CX, FDA 510(k) K233043 | 11.9% |
| Gynius AB | Stockholm, Sweden | Gynocular battery binocular colposcope | 6.4% |
| CooperSurgical (Leisegang) | United States | OptiK stand-mounted optics, substitute | not hand-held |
| ATMOS MedizinTechnik | Lenzkirch, Germany | i View COLPO stand and chair systems, substitute | not hand-held |
| Karl Kaps | Asslar, Germany | Colposcopes with LED optics, substitute | not hand-held |

## How much does a hand-held colposcope cost per unit, from the UNICEF kit to AI-enabled video scopes?

Hand-held colposcopes realise USD 2,915 per unit on average in 2025. That average sits inside a band running from about USD 1,500 for basic smartphone adapters to about USD 6,000 for digital video units with image analysis software, before tender discounts.

The UNICEF catalogue entry gives the clearest public anchor: [USD 2,050](https://supply.unicef.org/s0004076.html) for a portable colposcope with 5x, 8x and 12x optical magnification, 30,000 lux LED light, HDMI output, a 2 to 4 hour battery, a three-year warranty and a four-week lead time. Douglas Insights calculates segment averages of USD 4,450 for digital video units, USD 2,180 for smartphone-based colposcopes and USD 2,336 for optical hand-held colposcopes.

The price leg adds 0.9% a year, taking the average to about USD 3,188 by 2035. Mix drives it: digital video and AI-scored units gain share faster than smartphone units cut list prices. Programme buyers pay 25% to 40% less than private clinics for comparable colposcopes because tenders bundle 50 or more units, and they pay separately for training and spare batteries. For context on capital budgets in adjacent scopes, see our [Hospital Endoscopy Equipment Market](https://www.douglasinsights.com/hospital-endoscopy-equipment-market/) report.

## Which FDA rules decide whether a smartphone colposcope needs a 510(k) before sale?

US rules split hand-held colposcopes in two groups under 21 CFR 884.1630. Product code PTZ is Class II and 510(k) exempt, but only for white light, green filter, no image analysis software and non-smartphone designs; everything else needs a cleared 510(k).

The [FDA classification entry](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=PTZ) lists those four exemption limits. A smartphone-based colposcope or one with AI scoring therefore files a 510(k) under product code HEX, which is how the Smart Scope CX reached the US market in 2024. Douglas Insights counts this as a moat worth roughly six to twelve months of review time for new entrants.

Clinical rules matter as much as device rules. WHO guidance calls for HPV DNA screening from age 30 every 5 to 10 years, and from 25 every 3 to 5 years for women living with HIV, with colposcopy or naked-eye visual inspection used to decide treatment. England moved HPV-negative participants aged 24.5 to 49 to a 5-year interval under the protocol GOV.UK published in July 2025, a policy that lowers referral counts per thousand women for colposcopes.

## Can green-filter image capture and AI scoring change colposcopy referral quality?

AI scoring already ships on 1 of the top 3 hand-held colposcope platforms, the market leader's. Douglas Insights models AI-capable units at 16.4% of 2025 shipments, about 4,240 colposcopes, rising as AI-ready units win tenders across both private and public buyers. Image quality, not magnification, now decides most comparisons.

MobileODT markets VisualCheck as comparing a captured image with thousands of prior expert-annotated exams and returning a risk score in under one minute. Periwinkle went the regulated route instead, taking the Smart Scope CX through a full 510(k) under product code HEX. Both claims put image quality, not magnification, at the centre of the buying decision. A colposcope that flags a CIN2+ risk lets a nurse decide on ablation the same day, which is the whole point of screen-and-treat.

The catch is evidence. Few randomised data compare AI-assisted hand-held colposcopes with expert colposcopists across mixed populations, so hospital buyers still treat the score as a second reader rather than a decision.

## What if 70% screening coverage arrives on time: how far could hand-held colposcope revenue run by 2035?

Base-case revenue for hand-held colposcopes reaches USD 149.1 million in 2035 on 6.1% volume and 0.9% price growth; a slower path ends at USD 118.4 million and a faster one at USD 187.1 million. Programme funding decides which path the market takes.

The slower case cuts volume growth to 4.2% and price growth to 0.4%, which is what happens if the 1.9 points of restraints all bite: longer intervals spread beyond England, another supplier exit like DYSIS in [April 2025](https://www.dysismedical.com/), and donor grants that stall. The faster case lifts volume to 8.0% and price to 1.4%, the path where national programmes chase the 70% screening target and more smartphone-based colposcopes follow the [June 2024](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233043) Smart Scope CX clearance into regulated channels.

Sensitivity is steep. Adding one point to annual hand-held colposcope unit growth lifts the 2035 value to USD 163.7 million, USD 14.6 million above base; taking one point away leaves USD 135.6 million. Outside forecasts we read span 3.1% to 8.4% a year for colposcopes and their hand-held subset, and our 7.06% sits in the upper half because smartphone-based units are counted in full.

## Douglas Exclusive: the Hand-Held Colposcope Burden-to-Revenue Matrix

The Burden-to-Revenue Matrix is a Douglas Insights model of hand-held colposcope spending built from 11 inputs. Those are six regional counts of new cervical cancer cases from the IARC GLOBOCAN fact sheet and our five regional revenue estimates for 2025. It divides each region's revenue share by its share of new cases.

| Region | Share of 2025 hand-held colposcope revenue | Share of new cervical cancer cases | Revenue per new case (USD) | Burden-to-revenue ratio |
| --- | --- | --- | --- | --- |
| North America | 31.7% | 2.6% | 1,550 | 12.42 |
| Europe | 27.5% | 9.7% | 351 | 2.82 |
| Asia Pacific | 24.5% | 56.1% | 55 | 0.44 |
| Latin America | 8.9% | 11.0% | 101 | 0.81 |
| Middle East and Africa | 7.4% | 20.6% | 45 | 0.36 |

The finding is blunt: North America spends about USD 1,550 on hand-held colposcopes per new cervical cancer case, while the Middle East and Africa spend about USD 45, a gap of roughly 34 to 1. Asia Pacific carries 56.1% of cases, counting 336,441 in Asia and 2,610 in Oceania, but only 24.5% of revenue. The world average is about USD 125 of colposcope spending per new case against 604,196 cases. Regions with a ratio under 1.0 are where the 10.43% and 9.6% growth rates come from, and they are where vendors with sub-USD 2,500 colposcopes will win.

## How the model counts 25,870 hand-held colposcopes and checks the USD 75.4 million total?

The model multiplies 25,870 hand-held colposcopes shipped in 2025 by a USD 2,915 average realised price to reach USD 75.4 million. It then compounds 6.1% volume and 0.9% price growth for ten years to USD 149.1 million, and every product and regional split sums back to those totals.

Units sum from three product builds: 7,820 digital video, 10,046 smartphone-based and 8,004 optical colposcopes. Values sum the same way to USD 75.4 million, and the three 2035 product values total USD 148.6 million, within 0.4% of the headline. Five regional models sum to USD 75.4 million in 2025 and USD 149.1 million in 2035 with no residual. Douglas Insights cross-checked the 2025 total against four outside colposcope estimates; the closest hand-held figure was 3.7% below ours, and the UNICEF USD 2,050 kit price sits 29.7% under our blended average, consistent with tender discounts. In all, the model draws on the 11 matrix inputs, three product price bands, four outside estimates and four dated regulatory and company events.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Digital video hand-held colposcopes | 46.1% | $34.8 Mn |
| Smartphone-based colposcopes | 29.1% | $21.9 Mn |
| Optical hand-held colposcopes | 24.8% | $18.7 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 75.4 | 80.7 | 149.1 | 7.06% |
| North America | 23.9 | 25.1 | 39.7 | 5.2% |
| Europe | 20.7 | 21.7 | 33.7 | 5% |
| Asia Pacific | 18.5 | 20.3 | 46.3 | 9.6% |
| Latin America | 6.7 | 7.2 | 14.3 | 7.9% |
| Middle East and Africa | 5.6 | 6.2 | 15.1 | 10.43% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 75.4 | USD million |
| Market size 2035 | 149.1 | USD million |
| Revenue CAGR 2026-2035 | 7.06 | percent |
| Volume CAGR 2026-2035 | 6.1 | percent |
| Price per colposcope CAGR 2026-2035 | 0.9 | percent |

## Frequently asked questions

### What does a hand-held colposcope cost a programme buyer?

USD 2,050 through the UNICEF catalogue for a portable kit with stand, battery and green filters, against a 2025 market average of USD 2,915 per unit across all channels.

### What is the Hand-Held Colposcopes market worth in 2025 and 2035?

USD 75.4 million in 2025, rising to USD 149.1 million in 2035 on 6.1% annual unit growth and 0.9% annual price growth, a 7.06% revenue CAGR.

### How many hand-held colposcopes ship each year?

25,870 units in 2025 by Douglas Insights count: 7,820 digital video, 10,046 smartphone-based and 8,004 optical colposcopes.

### Why do smartphone colposcopes outgrow video and optical units?

10.1% a year by value, because nurse-led screen-and-treat and telecolposcopy reward a low-cost capture device that uploads images for remote review.

### Does a smartphone-based colposcope need FDA clearance?

510(k) clearance is needed: the PTZ exemption under 21 CFR 884.1630 covers only white light, green filter, no image analysis software and non-smartphone designs.

### Which suppliers lead hand-held colposcopes?

35.5% of 2025 revenue sits with MobileODT, Periwinkle Technologies and Gynius by Douglas Insights estimate, with MobileODT the leader at about 17.2%.

### Where is device spending lowest relative to cervical cancer burden?

USD 45 per new case in the Middle East and Africa versus USD 1,550 in North America, per the Douglas Insights Burden-to-Revenue Matrix.

### What happens to the 2035 figure if unit growth is one point higher?

USD 163.7 million in 2035, USD 14.6 million above the USD 149.1 million base case.

## Sources

- [UNICEF Supply Division, Colposcope, portable, incl stand and accessories (S0004076)](https://supply.unicef.org/s0004076.html)
- [US Food and Drug Administration, 510(k) K233043 Smart Scope CX](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233043)
- [US Food and Drug Administration, Product classification PTZ, colposcope exempt, 21 CFR 884.1630](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=PTZ)
- [US Food and Drug Administration, 510(k) K132423 The Gynocular](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K132423)
- [GOV.UK, Extended screening interval clinical pathway protocol](https://www.gov.uk/government/publications/extended-screening-interval-clinical-pathway-protocol/extended-screening-interval-clinical-pathway-protocol)
- [World Health Organization, Cervical cancer fact sheet](https://www.who.int/news-room/fact-sheets/detail/cervical-cancer)
- [IARC Global Cancer Observatory, Cervix uteri fact sheet](https://gco.iarc.who.int/media/globocan/factsheets/cancers/23-cervix-uteri-fact-sheet.pdf)
- [DYSIS Medical, DYSIS Medical company notice](https://www.dysismedical.com/)

## How to cite

Douglas Insights, "Hand-Held Colposcopes Market", DI-HC-10570, updated 2026-10-07, https://www.douglasinsights.com/hand-held-colposcopes-market/